Proposal to list riluzole for the treatment of amyotrophic lateral sclerosis (motor neurone disease)
8 August 2013
PHARMAC is seeking feedback on a provisional agreement with Sanofi-Aventis to fund riluzole (Rilutek) for the treatment of amyotrophic lateral sclerosis (ALS, also known as motor neurone disease) from 1 October 2013 subject to the Special Authority and hospital access restrictions outlined on the following page.
PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 5 pm on Thursday 22 August 2013 to:
Senior Therapeutic Group Manager
Fax: 04 460 4995
Post: PO Box 10 254, Wellington 6143
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Last updated: 2 March 2016